@kenzzzieb_glp's GLP-1 video claims need context

What did @kenzzzieb_glp actually say?

She said she has been on "setbound" (Zepbound, tirzepatide) for seven months, dropped from a size 18 to a size large, and moved out of plus-size sections entirely. Her framing is personal testimony, not medical advice. She is sharing her own results and inviting questions from followers. To her credit, she never tells anyone to take a specific dose, and she never claims tirzepatide will cure anything. The video is essentially a before-and-after clothing moment, which is one of the most common formats in the GLP-1 creator space. That does not make it automatically misleading, but it does carry real risks around expectation-setting, which we will get into.

The claim is not that everyone will drop four clothing sizes in seven months. But 108,900 views means a lot of people are watching, and many will absorb exactly that expectation without the nuance the creator did not provide.

Does the science back this up?

Yes, results like hers are within the documented range for tirzepatide, but they are on the higher end. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on the highest dose of tirzepatide (15 mg) lost an average of 20.9 percent of body weight over 72 weeks. Seven months is roughly 30 weeks, so her timeline is shorter than the full trial period.

A size 18 to a size large is roughly a four-size drop, which is plausible depending on starting weight, but not the median outcome. Average results in SURMOUNT-1 were significant, but the distribution matters. Some participants lost far less. Jastreboff's team also noted that 91 percent of participants on the highest dose achieved at least 5 percent weight loss, but fewer than half reached 25 percent or more. Her results appear real and achievable, but they are not average. Viewers should know that before they book an appointment expecting the same.

What did they get wrong (or right)?

She got the enthusiasm right without overclaiming on the mechanism. She never says tirzepatide is making her healthy, curing her of anything, or that she did nothing else. That restraint is actually unusual in this content category and deserves credit.

What she got wrong, mostly by omission, is the complete silence on what else was happening. Did she change her eating habits? Did her prescriber adjust her dose along the way? Did she experience side effects? The SURMOUNT-1 data came from a controlled trial with structured dietary counseling alongside medication. Real-world adherence data, including from Wharton et al. in a 2023 Obesity analysis, suggests outcomes vary considerably when behavioral support is absent.

She also mispronounces the drug name as "setbound," which is trivial but worth flagging because viewers searching for the drug may get confused. The brand name is Zepbound. The active ingredient is tirzepatide, which also acts on GIP receptors in addition to GLP-1, making it a dual agonist, a distinction that matters clinically.

What should you actually know?

Tirzepatide (Zepbound) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is not a quick fix, and it is not equally effective for everyone. Results like hers exist in the data, but they sit in the upper range of outcomes.

A few things the video does not mention that you should know before starting:

• Gastrointestinal side effects, including nausea, vomiting, and constipation, affect a significant portion of users, particularly during dose escalation. The SURMOUNT-1 trial reported GI adverse events in over 80 percent of participants on higher doses at some point.
• Weight loss on GLP-1 and GIP agonists often slows or plateaus after six to twelve months. Seven months may represent a period before that plateau hits.
• Discontinuation rates are high in real-world settings. A 2023 analysis by Wilding et al. noted that many patients stop within the first year due to cost, access, or side effects.
• Clothing size changes are not a standardized medical outcome. Body composition matters too. Muscle preservation during GLP-1-assisted weight loss is an active area of research.

Her story is real. Her results are possible. They are not guaranteed, and the video format does not give you the full picture.